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than on rare, serious outcomes. As a result, the samples
are too small to estimate the financial burden of less com-
mon outcomes; underestimation of the economic value of
these agents may occur. To illustrate, we examined the
cost of a less common, but serious outcome of chemo-
therapy, thrombocytopenia-related bleeding, in large and
small samples of cancer patients. METHOD: The cost of
1562 chemotherapy cycles in 612, randomly-chosen can-
cer patients was estimated from retrospective review of
medical and administrative databases. Cost was esti-
mated using a resource-based strategy (pharmaceuticals,
hospital and clinic costs, transfusions) from the pro-
vider’s perspective, in 1999 dollars. Twelve random,
10% samples of the cycles were selected, approximating
the size of most growth factor trials. Mean costs were
compared with two-tailed t-tests. RESULTS: Using the
entire sample, cycles with thrombocytopenia were more
expensive than those without ($7933 vs 4875, p 
0.0001). Cycles with bleeding were more expensive than
those without ($13,728 vs $7374, p  0.0001). They
were comparable in the costs of all inpatient and outpa-
tient services except monitoring ($538 vs $472, p 
0.01), transfusions to prevent bleeding ($1367 vs $758,
p  0.007), and bleeding treatment ($4702 vs $0, p 
0.0001). However, the cost of cycles with bleeding
(range: $8289–$16,277) was significantly higher than cy-
cles without bleeding (range: $5796–$8872) in only 5 of
the 12 small samples. CONCLUSIONS: The economic
impact of uncommon, but expensive outcomes should be
examined in samples large enough to permit calculation
of stable estimates of cost. The high cost of rare out-
comes such as bleeding will be better appreciated, as will
the importance of avoiding such episodes by preventing
thrombocytopenia.
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OBJECTIVES: In this study we compared outcomes and
costs between three treatments options (mastectomy
(MRM), breast conservation surgery with radiation (BC-
SRT), and breast conservation surgery only (BCSO)) for
elderly women with localized breast cancer. METHODS:
The sample was a national random sample from Medi-
care claims of 2,821 elderly women treated between
1992 to 1994 for localized breast cancer. Data on patient
preferences were collected in patient interviews con-
ducted in 1997. The outcomes studied were 5-year sur-
vival, Quality Adjusted Life Years (QALY), total costs
and cost/QALY. For each outcome we used univariate,
multivariate and instrumental variable analysis to com-
pare the differences between treatments. The instrumen-
tal variables used were geographic region, and distance to
nearest radiation facility. RESULTS: There were 1813
patients who received MRM, 704 who received BCSRT,
and 304 who received BCSO. The multivariate analysis
showed significantly higher survival for BCSRT relative
to MRM (4.21 vs. 4.13) and significantly higher QALYs
(3.50 vs. 3.45), but the IV analysis found an insignificant
difference opposite in sign. Costs were significantly
higher for BCSRT relative to MRM ($54,073 vs.
$37,327 in multivariate analysis). The cost-effectiveness
ratio of BCSRT relative to MRM is $334,920/QALY
(CI:$80,000 to NW) per QALY using multivariate esti-
mates and dominated using IV estimates. CONCLU-
SION: Survival and QALYs are statistically higher in tra-
ditional analyses of the BCSRT group relative to MRM,
but the IV analysis suggests an upward bias due to the se-
lection of healthier patients into BCSRT. This finding is
consistent with previous studies. Costs are unequivocally
higher in the BCSRT group suggesting BCSRT is not a
cost-effective option relative to MRM. Supplemental
analyses suggests that the presence of choice between
MRM and BCSRT raises the quality of life for all elderly
women independent of the choice that is made. Thus,
choice is costly but valuable.
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OBJECTIVE: This study assesses the health state prefer-
ences for adverse effects of chemotherapy on healthy
individuals. Time trade off (TTO), Standard Gamble
(SG), and Visual Analogue Scale (VAS) scores were com-
pared between side-effects and across two time points.
METHOD: A convenience sample of healthy pharmacy
students self-administered a questionnaire of TTO, SG
and VAS preferences for 12 different chemotherapy-related
side-effects ranging from anorexia to severe nausea. Re-
spondents completed the questionnaire on two separate
occasions separated by 2 weeks. RESULTS: Ninety-three
students completed at least one survey; 53 subjects com-
pleted both surveys (57%). The mean age of the sample
was 25 years; 21% were male. While no missing values
were seen in VAS questions, 23 missing responses were
noted in the TTO and 72 in the SG. TTO had the highest
test-retest correlation (ranging from 0.35 to 0.75) and
VAS had the lowest correlation (ranging from 0.29 to
0.65). The order of the preference measures was consis-
tent across nine of the twelve side-effects. The widest
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range of preferences occurred in the VAS, with the mean
score for severe nausea rated at 0.27, and anorexia at
0.82. The TTO and SG ranges were narrower than the
VAS (0.55 to 0.90, and 0.80 to 0.95, respectively). Con-
sistent with other studies, the lowest median score for all
three preference measures was severe nausea. CONCLU-
SION: Similar scores were obtained from the three meth-
ods to estimate preferences for cancer related health
states, although the narrowness of the TTO/SG distribu-
tions may limit the ability to distinguish between the 12
side-effects. The methods were not equivalent in ease of
administration as shown by the number of missing items
in the TTO/SG. Additional comparisons across these
three methods and different populations would assist in
determining the association between side effects and pref-
erences.
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OBJECTIVE: To characterize the antineoplastic treat-
ment of newly diagnosed breast cancer patients in a man-
aged care population. METHODS: Adult subjects con-
tained within PharMetric’s Integrated Outcomes database
possessing a diagnosis of breast cancer (ICD-9-CM 
174) followed by a procedure code for chemotherapy
during 1997–1999 were eligible for study inclusion. Pa-
tients with diagnoses for other neoplasms and pre-diag-
nosis treatment were excluded. Utilization of antineo-
plastic agents, radiation therapy (RT) and mastectomy
during the 6-month post-diagnosis period was measured.
RESULTS: 6,652 patients met the inclusion criteria. The
mean age was 53.7 years. 3,396 (51.1%) patients re-
ceived RT, while 3,469 (52.2%) patients underwent mas-
tectomy. Patients 61 year of age and older were signifi-
cantly less likely to undergo RT or mastectomy as
compared to younger patients (p  0.0001). Doxorubicin
and cyclophosphamide were extensively used in younger
patients (ADR: 32.7% in 71 vs. 64.4% in 40; cyclo-
phosphamide: 53.3% in 71 vs. 73.2% in 71). In con-
trast, fluorouracil and methotrexate appeared to be the
drug of choice in elderly (5-FU: 49.1% in 71 vs. 33.3%
in 41; MTX: 30.9% in 71 vs. 19.8% in 41). Use of
paclitaxol was consistent across all age categories
(24.4%). Elderly were less likely to undergo partial mas-
tectomy (8.7% in 71 vs. 23.1% in 41). The difference
in the rate of modified radical mastectomy between age
groups was less pronounced (22.3% in 71 vs. 29.5% in
41). After adjusting for age, RT and health plan identi-
fier, the administration of cyclophosphamide or doxoru-
bicin was more likely to follow any mastectomy, while
the association between mastectomy and fluorouracil use
was limited to modified radical. RT was likely to be used
as adjunct therapy to all antineoplastics, with the excep-
tion of cyclophosphamide. CONCLUSIONS: The elderly
appeared to be treated less aggressively with anti-neo-
plastic agents. The choice of agent is governed by age and
the mode of other treatments.
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OBJECTIVE: This study aims to estimate the non chemo-
therapy costs of treatment of advanced metastatic colo-
rectal cancer from the perspective of the UK National
Health Service. METHODS: Resource use collected dur-
ing comparative clinical trials often is insufficient in de-
termining the actual costs of patient management. Large
data bases can be used to estimate patient health care re-
source consumption, but these are not always available.
Soliciting expert opinion from clinicians may provide the
only reasonable data source. A questionnaire was devel-
oped to obtain resource utilization for routine treatment
and monitoring, adverse event management and other
clinical parameters in the first line setting. Responses
were obtained from five oncologists from various centres
in the UK with experience of treating advanced meta-
static colorectal cancer with chemotherapy. Data on sec-
ond line treatment came from resource use collected dur-
ing a trial. RESULTS: The clinicians estimated that 40%
of first line patients would receive only palliative care at
disease progression and 60% would receive second line
therapy. Resources included physicians, acute care ad-
missions, labs, hospice, palliative drugs, community
nurses and radiology.
CONCLUSIONS: Chemotherapy drug costs are only a
part of the costs incurred in treating advanced colorectal
cancer. These results clearly show the substantial non-
chemotherapy costs throughout the remaining life of pa-
tients that also need to be considered when treating these
patients.
Non-Chemotherapy Costs
Average cost/
patient/week £
One time cost for insertion of tunneled 
catheter at start of chemotherapy 250
Non chemotherapy costs during 1st line 
chemotherapy 485
Non chemotherapy costs during disease
remission (1st time) 116
Non chemotherapy costs during 2nd line
chemotherapy (derived from trial) 108
During Terminal Palliative Care 256
